Promethera Biosciences, a Belgian biotechnology company developing Promethera HepaStem, a cell-based therapy for the treatment of in-born errors of metabolism and acquired liver diseases, has announced the resignation of Eric Halioua from his post as CEO of Promethera and all other functions within the company. He has decided to leave to concentrate on other projects.

As CEO of the company since it was founded in 2009, Eric Halioua was the driving force behind the operational and financial growth of Promethera Biosciences, working closely with Professor Etienne Sokal, the company’s scientific founder.

Eric Halioua was instrumental in setting up the staffing structure and in taking Promethera Hepastem into Phase I/II clinical trials for orphan diseases such as Crigler-Najjar syndrome and urea cycle disorder (UCD). The search for his successor has already begun. The chairman of the board of directors, Dr John Tchelingerian, will assume the role of acting CEO during the transition phase.

“On behalf of the board of directors and the company as a whole, we would like to extend our heartfelt thanks to Eric for his contribution to the successful growth of Promethera Biosciences since it was first established. We wish him all the very best in his plans for the future,” said Dr Tchelingerian.

“Promethera Biosciences has a highly talented team and attractive technology. I am very proud of what we have achieved together over the last six years. I wish the company every success,” said Eric Halioua.